In a nutshell This trial is examining the effectiveness of ultra-high-dose hypofractionated or single-dose radiotherapy for intermediate (medium) risk prostate cancer. The main outcome that will be measured will be the number of patients that experience side effects. This study is being conducted in New York City, NY, the US. The details...
Read MoreProstate cancer Posts on Medivizor
My Oncologist Doesn’t Believe Food Is Necessary
By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...
Read MoreWhat are the effects of radical prostatectomy without pelvic lymph node dissection in prostate cancer?
In a nutshell This study investigated the outcomes of radical prostatectomy (RP) without pelvic lymph node dissection (PLND) in patients with prostate cancer. The main finding was that 5 years after treatment, 100% of patients at low risk for cancer recurrence had survived. Some background PLND is surgery to remove the lymph nodes from the pelvis....
Read MoreWhat are the effects of salvage stereotactic radiotherapy (SSRT) in prostate cancer relapse after prostate surgery?
In a nutshell This study investigated the effects of salvage stereotactic radiotherapy (SSRT) in patients with prostate bed recurrence after prostate surgery. The main finding was that SSRT was effective at curing or delaying prostate cancer recurrence. Some background Almost 30% of men who undergo radical prostatectomy (complete removal of the...
Read MoreEvaluating the outcomes of cabazitaxel treatment for patients with prostate cancer
In a nutshell This study examined the effectiveness of cabazitaxel (Jevtana) in patients with prostate cancer that has spread. This study concluded that cabazitaxel improved patient outcomes more than conventional hormone therapy. Some background Androgen deprivation therapy (ADT) remains a standard treatment for patients with prostate cancer....
Read MoreEvaluating docetaxel plus hormone therapy for the treatment of metastatic prostate cancer
In a nutshell This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden. Some background One treatment for...
Read MoreEvaluating different radiotherapy doses for patients with prostate cancer
In a nutshell This study evaluated whether fewer sessions of radiotherapy at a higher dose was more effective than conventional radiotherapy for patients with prostate cancer. The authors found that fewer radiation sessions at a higher dose did not increase side effects. Some background Radiation therapy is an effective treatment for prostate...
Read MoreEvaluating the overall survival in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide
In a nutshell This study investigated the effect of apalutamide (Erleada) on survival in patients with castrate-resistant prostate cancer (CRPC). This study found that apalutamide had a positive effect on the survival of these patients. Some background One treatment option for patients with prostate cancer is androgen deprivation therapy...
Read MorePembrolizumab in men with metastatic castrate-resistant prostate cancer
In a nutshell This study aimed to investigate the use of pembrolizumab (Keytruda) for prostate cancer (PCa). This study found that pembrolizumab was associated with a decline in prostate-specific antigen (PSA; a tumor marker for PCa). Some background Pembrolizumab is a type of immunotherapy. It works by triggering your...
Read MoreLooking for patients with advanced prostate cancer to test a new treatment strategy
In a nutshell This phase 2 study will investigate cryosurgical freezing (CF) and intratumoral combination immunotherapy (ITI) in advanced prostate cancer (PC). The main outcome will be the reduction in prostate specific antigen (PSA). This trial is recruiting in California and Michigan, US. The details Metastatic prostate cancer (PC) is an...
Read MoreCan apalutamide improve outcomes for patients with metastatic, castration-sensitive prostate cancer?
In a nutshell This study investigated whether adding apalutamide (erleada) to androgen-deprivation therapy (ADT) would improve survival in patients with prostate cancer. The authors concluded that adding apalutamide to ADT improved outcomes for these patients. Some background Androgen deprivation therapy (ADT) is the standard treatment for patients...
Read MoreFocal high-intensity focussed ultrasound for the treatment of localized prostate cancer
In a nutshell This study aimed to evaluate the use of high-intensity focal ultrasound (HIFU) for the treatment of localized prostate cancer. This study found that HIFU is a safe treatment with good oncological results and minimal side-effects. Some background High-intensity focused ultrasound (HIFU) is a non-invasive technique that uses...
Read More
